Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 2/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 2/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4521461 | 0.89 | FFAR2 (0.38) | FFAR2HSD11B1KMT2ATRPA1MAOA | |
| SCHEMBL4521465 | 0.89 | FFAR2 (0.38) | FFAR2HSD11B1KMT2ATRPA1MAOA | |
| SCHEMBL4509292 | 0.88 | FFAR2 (0.43) | FFAR2KMT2AACEMME | |
| SCHEMBL4097126 | 0.85 | FFAR2 (0.43) | FFAR2HSD11B1KMT2ATRPA1MAOA | |
| SCHEMBL4093122 | 0.84 | TRPA1 (0.38) | FFAR2HSD11B1KMT2ATRPA1 | |
| SCHEMBL4512180 | 0.84 | FFAR2 (0.33) | FFAR2KMT2AACE | |
| SCHEMBL4087306 | 0.82 | FFAR2 (0.34) | FFAR2HSD11B1TRPA1MAOAMAOB | |
| SCHEMBL4087308 | 0.82 | FFAR2 (0.34) | FFAR2HSD11B1TRPA1MAOAMAOB | |
| SCHEMBL4089653 | 0.82 | FFAR2 (0.34) | FFAR2HSD11B1TRPA1MAOAMAOB | |
| SCHEMBL4337937 | 0.77 | TRPA1 (0.40) | FFAR2THRBALOX12KMT2ATRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203697-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203697-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | CLIC4, NR3C2, MAN2B1 | FFAR2 1593/4885HSD11B1 194/4885THRB 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.